EP1119315A4 - Administration de polyphosphates phosphoinositides dans les cellules - Google Patents

Administration de polyphosphates phosphoinositides dans les cellules

Info

Publication number
EP1119315A4
EP1119315A4 EP99952984A EP99952984A EP1119315A4 EP 1119315 A4 EP1119315 A4 EP 1119315A4 EP 99952984 A EP99952984 A EP 99952984A EP 99952984 A EP99952984 A EP 99952984A EP 1119315 A4 EP1119315 A4 EP 1119315A4
Authority
EP
European Patent Office
Prior art keywords
delivery
cells
phosphoinositide
polyphosphates
phosphoinositide polyphosphates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99952984A
Other languages
German (de)
English (en)
Other versions
EP1119315A2 (fr
Inventor
Glenn D Prestwich
Shoichiro Ozaki
Daryll B Dewald
Joseph Shope
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Utah State University USU
Original Assignee
University of Utah Research Foundation UURF
Utah State University USU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation UURF, Utah State University USU filed Critical University of Utah Research Foundation UURF
Publication of EP1119315A2 publication Critical patent/EP1119315A2/fr
Publication of EP1119315A4 publication Critical patent/EP1119315A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP99952984A 1998-09-30 1999-09-29 Administration de polyphosphates phosphoinositides dans les cellules Withdrawn EP1119315A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US396296 1995-02-28
US10248298P 1998-09-30 1998-09-30
US102482P 1998-09-30
US39629699A 1999-09-15 1999-09-15
PCT/US1999/022594 WO2000018949A2 (fr) 1998-09-30 1999-09-29 Administration de polyphosphates phosphoinositides dans les cellules

Publications (2)

Publication Number Publication Date
EP1119315A2 EP1119315A2 (fr) 2001-08-01
EP1119315A4 true EP1119315A4 (fr) 2002-04-17

Family

ID=26799415

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99952984A Withdrawn EP1119315A4 (fr) 1998-09-30 1999-09-29 Administration de polyphosphates phosphoinositides dans les cellules

Country Status (4)

Country Link
EP (1) EP1119315A4 (fr)
AU (1) AU6502699A (fr)
CA (1) CA2345532A1 (fr)
WO (1) WO2000018949A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1290213A2 (fr) 2000-05-31 2003-03-12 Promega Corporation Dosage pour kinases et phosphatases
CN1539021A (zh) 2001-06-11 2004-10-20 Ӧ���о�ϵͳARS�ɷݹ�˾ 氨基糖苷结合分子的新型亲近闪烁检测法
WO2005036169A2 (fr) * 2003-10-03 2005-04-21 Cumbre Inc. Sondes fluorescentes pour ribosomes et leur procede utilisation
WO2005063260A2 (fr) * 2003-12-22 2005-07-14 Oregon Health And Science University Procedes et composition pour prevenir des effets secondaires toxiques des medicaments a aminoglycosides
EP1704257A2 (fr) 2004-01-16 2006-09-27 Applera Corporation Essais fluorogeniques pour kinase et substrats
US7659088B2 (en) * 2006-05-22 2010-02-09 Aureogen Biosciences, Inc. Assay for inositol phosphorylceramide synthase activity
GB0920985D0 (en) * 2009-11-30 2010-01-13 Queen Mary & Westfield College Novel inositol phosphate derivatives
US10350235B2 (en) 2015-08-19 2019-07-16 Joseph Kost Cationic polysaccharides for delivery of phosphoinositides to cells for therapeutic purpose

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897384A (en) * 1983-05-26 1990-01-30 The Liposome Company, Inc. Drug preparations of reduced toxicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897384A (en) * 1983-05-26 1990-01-30 The Liposome Company, Inc. Drug preparations of reduced toxicity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GABEV E ET AL: "BINDING OF NEOMYCIN TO PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE (PIP2)", BIOCHIMICA ET BIOPHYSICA ACTA. BIOMEMBRANES, AMSTERDAM, NL, vol. 979, 1989, pages 105 - 112, XP001022649, ISSN: 0005-2736 *
See also references of WO0018949A3 *

Also Published As

Publication number Publication date
WO2000018949A9 (fr) 2000-08-31
EP1119315A2 (fr) 2001-08-01
AU6502699A (en) 2000-04-17
WO2000018949A2 (fr) 2000-04-06
WO2000018949A3 (fr) 2000-07-20
CA2345532A1 (fr) 2000-04-06

Similar Documents

Publication Publication Date Title
IL139247A0 (en) Hematopoietic stimulation
TW399786U (en) Improvememt of receptacle structure
PL343518A1 (en) (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
ZA986769B (en) Reduction of the fibrinogen level
EP1119315A4 (fr) Administration de polyphosphates phosphoinositides dans les cellules
GB9813051D0 (en) High energy chamber
EP1048300A4 (fr) Agent de desintegration
EP1044679A4 (fr) Liposomes
AU136492S (en) Canister
GB9912851D0 (en) Treating cells
DE69908936D1 (en) 2''-deoxyhygromycinderivate
GB9824718D0 (en) Humidifiers
GB2336672B (en) Level
GB9815233D0 (en) Improved nozzle
PL108753U1 (en) Electrophonophoresis chamber
GB9811459D0 (en) Nozzle
TW316675U (en) Improved level
TW361389U (en) Improved structure of the soil supply can
CA82961S (en) Outsole
CA84541S (en) Nozzle
TW384742U (en) Structure of the nozzle
PL55331Y1 (en) Manure chamber
TW342936U (en) Level
PL106344U1 (en) Sepulchral chamber
TW404408U (en) Ozonizer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010502

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/70 A, 7G 01N 33/50 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020301

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020522